- $4.32bn
- $4.10bn
- $1.39bn
Competition and Mkts - Merger Update: NRG Fleet / Specialist Fleet
LivaNova PLC reports results for the quarter ended June 30 - Earnings Summary
UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook
Brief: Livanova Demonstrates 84.5% Cumulative Response Rate With Polysync Programming In OSPREY Study
UK's LivaNova Q1 revenue beats analyst estimates
Brief: LivaNova Q1 Adjusted EPS USD 0.98 Vs. IBES Estimate USD 0.9
Brief: Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
LivaNova Q4 revenue, EPS tops expectations on cardiopulmonary market demand
Competition and Mkts - Merger Update: Welltower/multiple care homes
Rule 19.6(b) update and Rule 19.6(c) confirmation
Brief: Livanova Appoints Lucile Blaise As Global Head Of Commercialization, Obstructive Sleep Apnea
Medical tech firm LivaNova beats Q3 revenue expectations, raises 2025 guidance
Brief: Livanova To Announce Third-Quarter 2025 Results
LivaNova PLC reports results for the quarter ended June 30 - Earnings Summary
LivaNova beats estimates for Q2 revenue, raises FY guidance
Brief: Livanova Announces Core-Vns 24-Month Data Show Adjunctive Vns Therapy Is Associated With Substantial Reductions In Generalized Tonic-Clonic Seizures In People With Drug-Resistant Epilepsy
LivaNova PLC reports results for the quarter ended March 31 - Earnings Summary
Brief: LivaNova Announces 12-Month Data From Osprey Clinical Study For Moderate To Severe Obstructive Sleep Apnea, Demonstrating Strong Response And Durability Of Therapy
Update to Stated Post-Offer Intention Statements